The Business Cocktail

Aug 02, 2016

Juno Therapeutics recently acquired Redox Therapies and it’s vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist. The upfront consideration for the Redox Therapies acquisition was $10 million in cash.
UK-based Cell Medica expands its T cell immunotherapy program with the acquisition of privately-held Delenex Therapeutics
Evelo Biosciences, US based Microbiome Company working in oncology through characterization of cancer associated bacteria, and Epiva Biosciences, another microbiome company from Flagship VentureLabs, merged to create a leading immuno-microbiome platform company in the U.S.
Medivation Inc., an American biopharmaceutical company working for the development of novel therapeutics, enters confidentiality agreement with French Drugmaker, Sanofi, who agreed to terminate its consent solicitation.
AstraZeneca is considering $10 billion bid for Medivation Inc., an American biopharmaceutical company, according to reports, however no formal offers have been made.
Evelo Biosciences, a pioneer in Oncobiotics, and Mayo Clinic, U.S.A. entered into an exclusive research collaboration for Immuno-microbiome Cancer Therapies, for advance development of cancer-associated bacteria library, a key platform discovery tool of the former for the development of onco-microbials to treat cancer.

Article in PDF

Article in PDF

Uncomplicated Urinary Tract Infection Market Insight, Epidemiology and Market Forecast -2034